Innovative Therapeutics in Oncology and Neuroscience
Late-stage
KarXT
Robust Antipsychotic Effect Across Three Registrational Trials in Schizophrenia
Primary Endpoint: Change in Baseline PANSS Total Score vs. Placebo at Week 51
EMERGENT-1
KarXT (n = 83), placebo (n = 87)
EMERGENT-2
KarXT (n = 117),
placebo (n = 119)
Placebo
KarXT
EMERGENT-3
KarXT (n = 114),
placebo (n = 120)
****
*
p<0.05
p<0.01
p<0.0001
PANSS total change from baseline
20
-20
O-15
เก
Baseline
Week 2
Week 4 Week 5
11.6-point reduction at Week 5
(-17.4 KarXT vs. -5.9 placebo)
Cohen's d effect size = 0.75
°
un
-10
PANSS total change from baseline
-15
-20
-25
Baseline
HHHH
HH
Η
Week 2 Week 3 Week 4 Week 5
9.6-point reduction at Week 5
(-21.2 KarXT vs. -11.6 placebo)
Cohen's d effect size = 0.61
PANSS total change from baseline
C
20
-15
+0
in
0
Baseline
HHHH
HH
Week 2 Week 3 Week 4 Week 5
8.4-point reduction at Week 5
(-20.6 KarXT vs. -12.2 placebo)
Cohen's d effect size = 0.60
Cohen's d effect size compares favorably with other trials of antipsychotics (0.35 – 0.58) 2
46
Source: (1) Karuna corporate presentation, May 2023; (2) Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962..
Clinical Data -
NeuroscienceView entire presentation